Detail of "3443-82-1"

Reference

Additives for foods and pharmaceuticals

Additives for foods and pharmaceuticals. Kobayashi, Takaaki; Sekine, Seikichi; Maekawa, Yoshio; Suzuki, Hirohisa; Shimoda, Zenya; Ono, Ichiro (Ajinomoto Co., Inc., Japan). Eur. Pat. Appl. EP 104043 A2 28 Mar 1984, 50 pp. DESIGNATED STATES: R: DE, FR, GB, NL. (English). (European Patent Organization). CODEN: EPXXDW. CLASS: IC: A23D005-00; A23L001-34; A23C009-152; A23L002-38; A61K031-33. APPLICATION: EP 83-305367 14 Sep 1983. PRIORITY: JP 82-163732 20 Sep 1982; JP 83-23460 15 Feb 1983; JP 83-151348 19 Aug 1983; JP 83-151349 19 Aug 1983; JP 83-151350 19 Aug 1983; JP 83-151351 19 Aug 1983. DOCUMENT TYPE: Patent CA Section: 18 (Animal Nutrition) Section cross-reference(s): 1, 17 a-Monolinolein [2277-28-3] and (or) b-monolinolein [3443-82-1] is added to foods and pharmaceuticals to act as a serum cholesterol [57-88-5]-lowering agent. Thus, rats given feed contg. 1% cholesterol and 1% monolinolein for 19 days showed 146.6 mg cholesterol/dL serum, whereas control rats on the same feed without monolinolein showed 198.8 mg cholesterol/dL.

Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol

Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Ghafouri, Nazdar; Tiger, Gunnar; Razdan, Raj K.; Mahadevan, Anu; Pertwee, Roger G.; Martin, Billy R.; Fowler, Christopher J. (Department of Pharmacology and Clinical Neuroscience, Umea University, Umea 901/87, Swed.). British Journal of Pharmacology, 143(6), 774-784 (English) 2004 Nature Publishing Group. CODEN: BJPCBM. ISSN: 0007-1188. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) 1 The pharmacol. of monoacylglycerol lipase (MAGL) is not well understood. In consequence, the abilities of a series of analogs of 2-arachidonoylglycerol (2-AG) to inhibit cytosolic 2-oleoylglycerol and membrane-bound anandamide hydrolysis by MAGL and fatty acid amide hydrolase (FAAH), resp., have been investigated. 2 2-AG and its 1-regioisomer (1-AG) interacted with MAGL with similar affinities (IC50 values 13 and 17 mM, resp.). Shorter homologues of 2-AG (2-linoleoylglycerol and 2-oleoylglycerol) had affinities for MAGL similar to 2-AG. This pattern was also seen when the arachidonoyl side chain of arachidonoyl trifluoromethylketone was replaced by an oleoyl side chain. 3 Arachidonoyl serinol (IC50 value 73 mM) was a weaker inhibitor of MAGL than 2-AG. The IC50 values of noladin ether towards MAGL and FAAH were 36 and 3 mM, resp.Several substances with their cas registry numbers 3443-82-1 and 94421-68-8 may be metioned in this study. Arachidonoyl glycine interacted with FAAH (IC50 value 4.9 mM) but only weakly interacted with MAGL (IC50 value > 100 mM). 4 a-Methyl-1-AG had similar potencies towards MAGL and FAAH (IC50 values of 11 and 33 mM, resp.). O-2203 (1-(20-cyano-16,16-dimethyl-eicosa-5,8,11,14-tetraenoyl) glycerol) and O-2204 (2-(20-hydroxy-16,16-dimethyl-eicosa-5,8,11,14-tetraenoyl) glycerol) were slightly less potent, but again affected both enzymes equally. a-Methyl-1-AG, O-2203 and O-2204 interacted only weakly with cannabinoid CB1 receptors expressed in CHO cells (Ki values 1.8, 3.7 and 3.2 mM, resp., compared with 0.24 mM for 1-AG) and showed no evidence of central cannabinoid receptor activation in vivo at doses up to 30 mg kg-1 i.v. 5 It is concluded that compds. like a-Methyl-1-AG, O-2203 and O-2204 may be useful as leads for the discovery of selective MAGL inhibitors that lack direct effects upon cannabinoid receptors. .